@ARTICLE{
author={Siefker-Radtke Arlene O|,Currie Graeme|,Abella Esteban|,Vaena Daniel A|,Kalebasty Arash Rezazadeh|,Curigliano Giuseppe|,Tupikowski Krzysztof|,Andric Zoran G|0000-0002-1495-2729,Lugowska Iwona|,Kelly William Kevin|},
year={2019},
title={FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
}